S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65

Merck & Co., Inc. Stock Competitors

-1.18 (-1.51 %)
(As of 10/18/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume13.06 million shs
Average Volume12.33 million shs
Market Capitalization$195.30 billion
P/E Ratio35.23
Dividend Yield3.32%


Should you be buying Merck & Co., Inc. stock or one of its competitors? The main competitors of Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.

Merck & Co., Inc. vs.

Pfizer (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Pfizer has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.8%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 12 consecutive years and Merck & Co., Inc. has increased its dividend for 10 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer currently has a consensus price target of $44.00, suggesting a potential upside of 6.49%. Merck & Co., Inc. has a consensus price target of $93.31, suggesting a potential upside of 20.95%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
0 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
Merck & Co., Inc.
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)

Pfizer has a net margin of 23.06% compared to Merck & Co., Inc.'s net margin of 11.48%. Merck & Co., Inc.'s return on equity of 50.93% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer 23.06% 26.49% 10.73%
Merck & Co., Inc. 11.48% 50.93% 16.15%

64.9% of Pfizer shares are owned by institutional investors. Comparatively, 71.8% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer received 547 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 72.52% of users gave Pfizer an outperform vote while only 67.43% of users gave Merck & Co., Inc. an outperform vote.

PfizerOutperform Votes
Underperform Votes
Merck & Co., Inc.Outperform Votes
Underperform Votes

In the previous week, Pfizer had 39 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 56 mentions for Pfizer and 17 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.24 beat Pfizer's score of 0.24 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
12 Very Positive mention(s)
17 Positive mention(s)
17 Neutral mention(s)
1 Negative mention(s)
5 Very Negative mention(s)
Merck & Co., Inc.
5 Very Positive mention(s)
6 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)

Pfizer has higher earnings, but lower revenue than Merck & Co., Inc.. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$41.91 billion5.53$9.62 billion$2.2218.61
Merck & Co., Inc.$47.99 billion4.07$7.07 billion$5.9412.99


Merck & Co., Inc. beats Pfizer on 12 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Merck & Co., Inc. (NYSE:MRK) vs. Its Competitors

TypeMerck & Co., Inc.Pharmaceutical IndustryMedical SectorNYSE Exchange
Dividend Yield3.32%2.53%1.96%2.77%
P/E Ratio35.2323.9032.4327.59
Net Margins11.48%-3,378.35%-3,880.25%-85.67%

Merck & Co., Inc. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Johnson & Johnson
2.7714 of 5 stars
+8.1%$421.51B$82.58B24.08134,500Earnings Report
3.0029 of 5 stars
Eli Lilly and
2.8764 of 5 stars
+63.6%$229.19B$24.54B35.832,020Upcoming Earnings
Dividend Announcement
3.54 of 5 stars
Bristol-Myers Squibb
3.3648 of 5 stars
-7.0%$126.53B$42.52B-25.0830,250Analyst Revision
2.3548 of 5 stars
+24.0%$96.08B$6.68B50.8111,300Dividend Announcement
Horizon Therapeutics Public
2.345 of 5 stars
Royalty Pharma
3.0164 of 5 stars
-11.5%$22.48B$2.12B23.1451Dividend Announcement
Analyst Downgrade
Short Interest ↑
News Coverage
Jazz Pharmaceuticals
3.0183 of 5 stars
2.7214 of 5 stars
-5.5%$5.99B$5.06B-17.4211,500News Coverage
Nektar Therapeutics
2.2514 of 5 stars
Pacira BioSciences
2.6242 of 5 stars
-5.2%$2.36B$429.65M13.58624Analyst Report
Analyst Revision
News Coverage
Corcept Therapeutics
2.7998 of 5 stars
Supernus Pharmaceuticals
1.9864 of 5 stars
Endo International
2.0898 of 5 stars
-16.5%$971.36M$2.90B14.863,397Analyst Upgrade
2.0848 of 5 stars
BioDelivery Sciences International
2.6583 of 5 stars
+10.6%$402.28M$156.47M12.36176Short Interest ↓
Analyst Revision
News Coverage
1.9209 of 5 stars
-50.8%$354.35M$73.81M-2.48277Analyst Report
Gap Down
High Trading Volume
Paratek Pharmaceuticals
2.0648 of 5 stars
-6.5%$233.24M$46.92M-4.02197News Coverage
Assembly Biosciences
2.0943 of 5 stars
2.1314 of 5 stars
Cumberland Pharmaceuticals
1.5915 of 5 stars
N/A-9.2%$41.07M$37.44M-276,000.0090Short Interest ↓
Gap Up
This page was last updated on 10/19/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.